Summary of Recent Deal Activity
- PDF / 71,915 Bytes
- 5 Pages / 586 x 792 pts Page_size
- 62 Downloads / 167 Views
Summary of Recent Deal Activity Drug Discovery Technologies Companies Amgen, Galapagos
Type of Deal R&D agreement
Details Galapagos’ services division BioFocus has extended its drug discovery collaboration with Amgen for biology, computational/medicinal chemistry services and supply of biologically directed library compounds for Amgen’s ion channel lead discovery programs throughout 2006. Under the terms of the extended agreement, BioFocus will continue to provide Amgen with drug discovery expertise for multiple ion channel targets, including assay development, high-throughput screening, chemistry and molecular informatics. In return, Galapagos will receive an upfront fee of $US2.3 million. Should all clinical and commercial events on a program be achieved, potential payments may exceed $US30 million. Applied Licensing Applied Biosystems has granted a license to QIAGEN under the expanded Applied Biosystems Biosystems, agreement PCR (polymerase chain reaction) licensing program. The expanded program includes patents for QIAGEN real-time PCR and other important PCR-related technologies not licensed under the previous PCR licensing program. Artemis Licensing German company Artemis Pharmaceuticals and the UK Medical Research Council’s Protein Pharmaceuticals agreement Phosphorylation Unit (MRC PPU) have signed a license agreement. The MRC PPU has granted Artemis rights to distribute and use certain genetically engineered mouse models developed at the unit. Under this agreement Artemis will sell these models, which have innovative modifications in certain key genes that code for proteins or enzymes known as kinases that affect many signaling pathways in the body. Protein kinases play an essential role in signaling pathways and disregulated kinase activity is a frequent cause of severe illnesses such as cancer, diabetes and cardiovascular and inflammatory diseases. The transgenic models, designed by a research team at the MRC PPU, serve as valuable exploration tools to discover the mechanisms or pathways underlying human disease. They can be used in academic research and drug discovery to identify and characterize new inhibitors of particular kinases. These inhibitors may then be developed as potential treatments for a wide range of disease. AstraZeneca, Licensing AstraZeneca has licensed access to Eidogen-Sertanty’s Target Informatics Platform™. Under the Eidogen-Sertanty agreement agreement, scientists at AstraZeneca R&D Boston will access Eidogen-Sertanty’s Target Informatics Platform and EVE™ Comparative Visualization software to assist drug discovery efforts within their cancer and anti-infective therapeutic programs. AstraZeneca, R&D and Targacept and AstraZeneca have entered into an exclusive global license and research Targacept licensing agreement collaboration agreement for the development and commercialization of Targacept’s proprietary compound ispronicline (TC 1734) to treat Alzheimer disease, cognitive deficits in schizophrenia and other cognitive disorders. The agreement also provides for a 4-year resear
Data Loading...
